Exagen Inc. (XGN) Tops Q1 EPS by 2c

Exagen Inc. (NASDAQ: XGN) reported Q1 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $15.5 million versus the consensus estimate of $14.66 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Methanex to idle Trinidad Titan plant after gas contract talks fail
• FDA selects seven participants for precheck pilot program to advance U.S. drug manufacturing